General Information of Drug (ID: DM31JAZ)

Drug Name
3-(3-(carbamoyl)benzamido)propanoic acid Drug Info
Synonyms CHEMBL219603; 3-(3-(carbamoyl)benzamido)propanoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44418280
TTD Drug ID
DM31JAZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
XEMILOFIBAN DMBRYT8 Cardiovascular disease BA00-BE2Z Discontinued in Phase 3 [2]
DMP-802 DMDK6HP N. A. N. A. Discontinued in Phase 1 [3]
SC-47643 DMIE039 N. A. N. A. Terminated [4]
SB-223245 DM3JQCF N. A. N. A. Terminated [5]
L-709780 DMB3ZTI N. A. N. A. Terminated [6]
Ro-43-8857 DM4VY8S N. A. N. A. Terminated [3]
SKF-107260 DMM8F0V N. A. N. A. Terminated [7]
L-738167 DMO69X8 N. A. N. A. Terminated [3]
DMP-757 DMGNUXC N. A. N. A. Terminated [8]
Ro-43-5054 DMPNHF0 N. A. N. A. Terminated [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Integrin alpha-2 (ITGA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
E7820 DMZRXTL Colorectal cancer 2B91.Z Phase 2 [9]
3-(3-(benzamido)-5-nitrobenzamido)propanoic acid DMY4VX2 Discovery agent N.A. Investigative [1]
3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid DM2K51S Discovery agent N.A. Investigative [1]
MAGGIEMYCIN DMSQL19 Discovery agent N.A. Investigative [10]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-2 (ITGA2) TTSJ542 ITA2_HUMAN Inhibitor [1]
ITGB3 messenger RNA (ITGB3 mRNA) TTJA1ZO ITB3_HUMAN Inhibitor [1]

References

1 Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7.
2 Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65.
3 Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73.
4 Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41.
5 Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6.
6 Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
7 Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
8 Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
9 Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
10 Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. J Med Chem. 2007 May 31;50(11):2742-6.